About the Project
Pseudomonas aeruginosa is a Gram-negative opportunistic pathogen associated with high morbidity and mortality in humans. P. aeruginosa is frequently isolated from patients with Cystic Fibrosis, AIDS and burns patients. In 2018, the World Health Organisation identified carbapenem-resistant P. aeruginosa as number two on the priority pathogen list for which there is an urgent need for the development of novel therapeutic strategies due increasing failure of first line antibiotics. P. aeruginosa is notorious for its ability to form biofilms both within the hospital-built environment and in immunocompromised individuals. Given the link between biofilm formation and poor treatment outcomes, the regulatory networks that control biofilm formation in P. aeruginosa are ideal targets for novel therapeutic intervention strategies.
This proposed research project aims to use high through put screening approaches to identify novel compounds that can disrupt the regulatory networks that control biofilm formation in P. aeruginosa. The mechanism of action of these candidates will then be explored using a range of classical microbiology, ‘omics and genetic approaches. Candidates that demonstrate activity against P. aeruginosa will be tested against other clinically relevant Gram-negative pathogens such as Acinetobacter baumannii. A range of model organisms will be used to determine the efficacy of these compounds in vivo.
Based on your current searches we recommend the following search filters.
Based on your current search criteria we thought you might be interested in these.